BMS' Deucravacitinib (BMS-986165) Demonstrate Superiority Over Amgen' Otezla (apremilast) in P-III POETYK PSO-1 Study for Plaque Psoriasis
Shots:
- The P-III POETYK PSO-1 study involves assessing deucravacitinib (6mg- qd) vs PBO & Otezla (apremilast) in 666 patients with moderate to severe plaque psoriasis
- The trial met its co-1EPs & 2EPs demonstrating deucravacitinib was superior to Otezla (apremilast) in the patients reaching a PASI 75 and sPGA 0/1 @16wks. The overall safety profile of deucravacitinib was consistent with previously reported P-II results
- Deucravacitinib (BMS-986165- PO) is the first & only novel selective TYK2 inhibitor- currently being evaluated in psoriasis- PsA- lupus- and IBD
Ref: Businesswire | Image: BMS
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com